CalciMedica announces publication of preclinical data in EMBO Molecular Medicine to support development of CRAC channel inhibitors for inflammatory bowel disease (IBD)
The study provides further validation of the broad potential benefit of CRAC channel inhibitors in inflammatory diseases The data show that the inhibition of Ca store-administered2+ Entry (SOCE) with a selective CRAC channel inhibitor reduced the severity of IBD in rat models La Jolla, California.And the August 9, 2022 /PRNewswire/ — CalciMedica Inc. (“CalciMedica” or … Read more